Immunotherapy Agents in Pancreatic Cancer

Margaret A. Tempero, MD, director, Pancreas Center, University of California, San Francisco, discusses the potential for immunotherapies in pancreatic cancer.

Clinical Pearls:

• Developing immunotherapy agents in this space is a work in progress
• Investigators at Johns Hopkins University School of Medicine have been looking at an autologous cell-based vaccine
• Antigen-specific vaccines are also in development for pancreatic cancer
• There is a need to “make room” for immunotherapies and determine their optimal use, especially with regard to immune checkpoint inhibitors, such as PD-1 and anti-CTLA-4